Literature DB >> 10564676

Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity.

I U Ali1, L M Schriml, M Dean.   

Abstract

PTEN/MMAC1 (phosphatase, tensin homologue/mutated in multiple advanced cancers) is a tumor suppressor protein that has sequence homology with dual-specificity phosphatases, which are capable of dephosphorylating both tyrosine phosphate and serine/threonine phosphate residues on proteins. The in vivo function of PTEN/MMAC1 appears to be dephosphorylation of phosphotidylinositol 3,4, 5-triphosphate. The PTEN/MMAC1 gene is mutated in the germline of patients with rare autosomal dominant cancer syndromes and in subsets of specific cancers. Here we review the mutational spectra of the PTEN/MMAC1 gene in tumors from various tissues, especially endometrium, brain, prostate, and ovary, in which the gene is inactivated very frequently. Germline and somatic mutations in the PTEN/MMAC1 gene occur mostly in the protein coding region and involve the phosphatase domain and poly(A)(6) stretches. Compared with germline alterations found in the PTEN/MMAC1 gene, there is a substantially increased frequency of frameshift mutations in tumors. Glioblastomas and endometrial carcinomas appear to have distinct mutational spectra, probably reflecting differences in the underlying mechanisms of inactivation of the PTEN/MMAC1 gene in the two tissue types. Also, depending on the tissue type, the gene appears to be involved in the initiation or the progression of cancers. Further understanding of PTEN/MMAC1 gene mutations in different tumors and the physiologic consequences of these mutations is likely to open up new therapeutic opportunities for targeting this critical gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10564676     DOI: 10.1093/jnci/91.22.1922

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  152 in total

1.  PTEN expression causes feedback upregulation of insulin receptor substrate 2.

Authors:  L Simpson; J Li; D Liaw; I Hennessy; J Oliner; F Christians; R Parsons
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  Redox regulation of PI 3-kinase signalling via inactivation of PTEN.

Authors:  Nick R Leslie; Deborah Bennett; Yvonne E Lindsay; Hazel Stewart; Alex Gray; C Peter Downes
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

3.  Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice.

Authors:  Hong Shen-Li; Susan Koujak; Matthias Szablocs; Ramon Parsons
Journal:  Cancer Biol Ther       Date:  2010-12-01       Impact factor: 4.742

4.  A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.

Authors:  Andrew J Armstrong; George J Netto; Michelle A Rudek; Susan Halabi; David P Wood; Patricia A Creel; Kelly Mundy; S Lindsay Davis; Ting Wang; Roula Albadine; Luciana Schultz; Alan W Partin; Antonio Jimeno; Helen Fedor; Phillip G Febbo; Daniel J George; Robin Gurganus; Angelo M De Marzo; Michael A Carducci
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

5.  Phosphatase and tensin homolog (PTEN) pseudogene expression in endometrial cancer: a conserved regulatory mechanism important in tumorigenesis?

Authors:  Yevgeniya J Ioffe; Katherine B Chiappinelli; David G Mutch; Israel Zighelboim; Paul J Goodfellow
Journal:  Gynecol Oncol       Date:  2011-10-15       Impact factor: 5.482

6.  PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

Authors:  Arjun Sood; Danielle McClain; Radhashree Maitra; Atrayee Basu-Mallick; Raviraja Seetharam; Andreas Kaubisch; Lakshmi Rajdev; John M Mariadason; Kathryn Tanaka; Sanjay Goel
Journal:  Clin Colorectal Cancer       Date:  2012-01-28       Impact factor: 4.481

Review 7.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

8.  FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment.

Authors:  Qiuping Ma; Wei Fu; Pengfei Li; Santo V Nicosia; Guido Jenster; Xiaohong Zhang; Wenlong Bai
Journal:  Mol Endocrinol       Date:  2008-12-12

9.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

10.  Pten haploinsufficiency accelerates formation of high-grade astrocytomas.

Authors:  Chang-Hyuk Kwon; Dawen Zhao; Jian Chen; Sheila Alcantara; Yanjiao Li; Dennis K Burns; Ralph P Mason; Eva Y-H P Lee; Hong Wu; Luis F Parada
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.